Skip to main content

Academic Detailing Embraced as a Method to Combat Opioids in Northern California

Posted in News on 11.17.2017

Kasier Health News recently reported that money from Obama-era grants is being used to fund academic detailing programs in California for the purpose of educating providers on the risks of prescribing opioids. To date, academic detailing programs has been used to address overprescribing of opioids a...


Pharmaco-Epi Community Responds to New Study re: Cost of Cancer Drugs

Posted in News on 9.15.2017

Pin pointing the dollar amount that it actually costs to bring a drug to market is a tricky business. Until recently, the most widely accepted estimate has come from Tufts Center for the Study of Drug Development, at $2.7 billion per drug.  Yet a new study published in JAMA places that number ...


With Drug Resistance, Prevention and Early Detection is Key

Posted in News on 7.13.2017

A news release from the World Health Organization (WHO) stated that gonorrhea bacteria are evolving in a way that makes the infection much harder to treat. Gonorrhea is a sexually transmitted infection (STI) that is generally curable with antibiotics. However, new data from various countries around ...


Post Editorial Reflects on Progress in HIV/AIDs Treatment and Prevention

Posted in News on 7.12.2017

The Washington DC Department of Health HIV/AIDS, Hepatitis, STD, and TB Administration (HAHSTA) recently published its Annual Epidemiology & Surveillance Report with good news, as noted by the editorial staff of the Washington Post. The report shows substantial progress being made in the D.C. a...


What Assault on FDA Authority Means for Public Health

Posted in News on 5.11.2017

In a piece recently published in The American Prospect, Alosa Health founder Dr. Jerry Avorn discusses regulatory trends around drug manufacturing and marketing as well as their consequences, making the case that diminishing FDA authority could have harmful effects on patients.  Specifically, ...


FDA Review Process Speedier than European Counterpart

Posted in News on 4.6.2017

The FDA has been getting flack from the U.S. President as well as the president’s nominee to lead the agency, Dr. Scott Gottlieb, on account of their approvals process, which has been characterized as “slow and burdensome”. Yet, a recent study published in the New England Journal ...


Proposed NIH Cuts Would Inhibit Medical Research

Posted in News on 3.30.2017

The current iteration of the federal budget proposed by the U.S. President would cut $1.2 billion to the National Institutes of Heath (NIH), though the budget needs to be approved in both houses of Congress before it can go into effect and thus modifications are possible.  The cuts target rese...


Ulterior Motive in Question with Drug Companies’ Charity

Posted in News on 2.16.2017

The Massachusetts U.S. Attorney’s Office is currently leading a nationwide  investigation into drug companies’ charitable contributions toward organizations that provide financial assistance to patients whose health conditions require expensive drugs. These organizations typically c...


Congress Says ‘Yes’ to Fast Track FDA Approvals

Posted in News on 12.9.2016

Last week Congress passed legislation addressing questions of healthcare regulation and public health funding. The 21st Century Cures Bill was able to gain easy approval in both the House and Senate because it contains provisions that appeal to both sides of the aisle and to various industry and pub...


Bill to Ease FDA Approval Draws Praise and Rebuke

Posted in News on 12.1.2016

Alosa Health founder Dr. Jerry Avorn was quoted in the Wall Street Journal regarding a healthcare bill scheduled for a vote in the House next week. The bill in question covers a breadth of topics from funding for biomedical research to opioid addiction to the FDA’s regulatory processes.  ...